Gene Therapy Products Reached to Market by 2021

Author:

Number of pages: 1-21
Year-Number: 2021-2

Abstract

Cell and gene therapy are targeted treatments for genetic illnesses that reduce life quality and shorten lifespan. Cell and gene therapy differ from traditional treatments in that they directly target the malfunctioning gene and can cure it in a single dose. Approvals for cell and gene therapy products have increased rapidly in recent years, particularly since 2017, and investment in this sector has increased. When we look at it, cell and gene therapy products continue to be the most expensive pharmaceuticals. The high cost of R&D technologies, the length of regulatory processes, and the difficulties of mass manufacturing are some of the causes of this high cost. The cell and gene therapy product market, which was $11.9 billion in 2021, is expected to reach $43.7 billion by 2024. This target is dependent on the FDA's announcement that it expects to approve 10-20 new cell and gene therapy products per year until 2025. We have compiled a list of 25 gene therapy products that have been approved by any institution through 2021. Some of these products were withdrawn from the market after they were launched for various reasons, which we have also mentioned here.

Keywords

Abstract

Cell and gene therapy are targeted treatments for genetic illnesses that reduce life quality and shorten lifespan. Cell and gene therapy differ from traditional treatments in that they directly target the malfunctioning gene and can cure it in a single dose. Approvals for cell and gene therapy products have increased rapidly in recent years, particularly since 2017, and investment in this sector has increased. When we look at it, cell and gene therapy products continue to be the most expensive pharmaceuticals. The high cost of R&D technologies, the length of regulatory processes, and the difficulties of mass manufacturing are some of the causes of this high cost. The cell and gene therapy product market, which was $11.9 billion in 2021, is expected to reach $43.7 billion by 2024. This target is dependent on the FDA's announcement that it expects to approve 10-20 new cell and gene therapy products per year until 2025. We have compiled a list of 25 gene therapy products that have been approved by any institution through 2021. Some of these products were withdrawn from the market after they were launched for various reasons, which we have also mentioned here.

Keywords